Anika Therapeutics, Inc.
$15.82
▼
-1.2%
2026-04-21 05:18:01
www.anika.com
NMS: ANIK
Explore Anika Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$213.74 M
Current Price
$15.82
52W High / Low
$16.02 / $7.87
Stock P/E
—
Book Value
$10.33
Dividend Yield
—
ROCE
-6.56%
ROE
-6.71%
Face Value
—
EPS
$-0.7
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
235
Beta
0.28
Debt / Equity
18.3
Current Ratio
4.72
Quick Ratio
3.86
Forward P/E
36.9
Price / Sales
1.89
Enterprise Value
$166.56 M
EV / EBITDA
-30.45
EV / Revenue
1.48
Rating
None
Target Price
$17.5
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BioAge Labs, Inc. | $18.8 | — | $820.58 M | — | -33.77% | -27.09% | $24 / $3.63 | $7.28 |
| 2. | Bausch Health Companies Inc. | $5.91 | 14.05 | $3.02 B | — | 9.85% | 4.36% | $11.97 / $6.06 | $-1.5 |
| 3. | BioCryst Pharmaceuticals, Inc. | $9.19 | 8.7 | $2.3 B | — | 107.2% | -88.68% | $11.31 / $6 | $-0.56 |
| 4. | Pacira BioSciences, Inc. | $24.9 | 143.33 | $1.01 B | — | 2.91% | 0.96% | $27.64 / $18.8 | $16.86 |
| 5. | Assertio Holdings, Inc. | $18.14 | — | $116.08 M | — | -12.35% | -28.25% | $20.45 / $8.55 | $14.63 |
| 6. | Apimeds Pharmaceuticals US, Inc. | $1.88 | — | $23.64 M | — | 126.09% | 209.61% | $40.31 / $1.61 | $0.65 |
| 7. | Prestige Consumer Healthcare Inc. | $58.68 | 14.89 | $2.78 B | — | 10.6% | 10.31% | $89.37 / $51.24 | $38.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 30.61 M | 27.82 M | 28.22 M | 26.17 M | -1.29 M | — |
| Operating Profit | 0.65 M | -3.23 M | -4.18 M | -4.28 M | 24.72 M | — |
| Net Profit | 0.29 M | -2.33 M | -3.97 M | -4.87 M | -21.86 M | — |
| EPS in Rs | 0.02 | -0.17 | -0.3 | -0.36 | -1.63 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 112.82 M | 119.91 M | 120.79 M | 113.83 M |
| Operating Profit | -11.05 M | -5.1 M | 0.84 M | 3.67 M |
| Net Profit | -10.88 M | -56.38 M | -82.67 M | -14.86 M |
| EPS in Rs | -0.81 | -4.21 | -6.17 | -1.11 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 190.27 M | 202.74 M | 270.63 M | 349.13 M |
| Total Liabilities | 46.8 M | 48.75 M | 58.37 M | 63.56 M |
| Equity | 143.47 M | 153.99 M | 212.26 M | 285.56 M |
| Current Assets | 103.36 M | 113.65 M | 163.31 M | 169.55 M |
| Current Liabilities | 21.91 M | 23.31 M | 31.06 M | 27.91 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 11.19 M | 5.4 M | -1.79 M | 4.41 M |
| Investing CF | -0.4 M | -8.33 M | -5.43 M | -7.49 M |
| Financing CF | -10.55 M | -12.73 M | -6.32 M | -4.85 M |
| Free CF | 4.36 M | -2.93 M | -7.21 M | -3.08 M |
| Capex | -6.83 M | -8.33 M | -5.43 M | -7.49 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -0.73% | 6.12% | — | — |
| Earnings Growth % | 31.79% | -456.34% | — | — |
| Profit Margin % | -47.02% | -68.44% | -13.05% | — |
| Operating Margin % | -4.25% | 0.7% | 3.22% | — |
| Gross Margin % | 63.38% | 68.33% | 64.33% | — |
| EBITDA Margin % | 2.52% | 12.47% | 15.95% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.